Label: LISINOPRIL tablet
- NDC Code(s): 67046-1045-3
- Packager: Coupler LLC
- This is a repackaged label.
- Source NDC Code(s): 68001-335
- Category: HUMAN PRESCRIPTION DRUG LABEL
- DEA Schedule: None
- Marketing Status: Abbreviated New Drug Application
Drug Label Information
Updated November 8, 2024
If you are a consumer or patient please visit this version.
- Download DRUG LABEL INFO: PDF XML
- Official Label (Printer Friendly)
-
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use LISINOPRIL TABLETS safely and effectively. See full prescribing information for LISINOPRIL TABLETS ...
-
Table of ContentsTable of Contents
-
BOXED WARNING
(What is this?)WARNING: FETAL TOXICITY - When pregnancy is detected, discontinue lisinopril as soon as possible - [see WARNINGS AND PRECAUTIONS ( 5.1)] . Drugs that act directly ...
-
1 INDICATIONS AND USAGE1.1 Hypertension - Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood ...
-
2 DOSAGE AND ADMINISTRATION2.1 Hypertension - Initial Therapy in adults: The recommended initial dose is 10 mg once a day. Dosage should be adjusted according to blood pressure response. The usual dosage range is 20mg to ...
-
3 DOSAGE FORMS AND STRENGTHS2.5 mg tablet is a white to off-white, round, biconvex, uncoated tablet with "LUPIN" debossed on one side and "2.5" on other side. 5 mg tablet is a pink coloured, round, biconvex, uncoated ...
-
4 CONTRAINDICATIONSLisinopril is contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer Lisinopril tablet USP within 36 hours of switching to or from ...
-
5 WARNINGS AND PRECAUTIONS5.1 Fetal Toxicity - Lisinopril can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of ...
-
6 ADVERSE REACTIONS6.1 Clinical Trials Experience - Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly ...
-
7 DRUG INTERACTIONS7.1 Diuretics - Initiation of lisinopril in patients on diuretics may result in excessive reduction of blood pressure. The possibility of hypotensive effects with lisinopril can be minimized by ...
-
8 USE IN SPECIFIC POPULATIONS8.1 Pregnancy - Risk Summary - Lisinopril can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters ...
-
10 OVERDOSAGEFollowing a single oral dose of 20 g/kg no lethality occurred in rats, and death occurred in one of 20 mice receiving the same dose. The most likely manifestation of overdosage would be ...
-
11 DESCRIPTIONLisinopril is an oral long-acting angiotensin converting enzyme (ACE) inhibitor. Lisinopril, a synthetic peptide derivative, is chemically described as ...
-
12 CLINICAL PHARMACOLOGY12.1 Mechanism of Action - Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to ...
-
13 NONCLINICAL TOXICOLOGY13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility - There was no evidence of a tumorigenic effect when lisinopril was administered for 105 weeks to male and female rats at doses up to 90 ...
-
14 CLINICAL STUDIES14.1 Hypertension - Two dose-response studies utilizing a once-daily regimen were conducted in 438 mild to moderate hypertensive patients not on a diuretic. Blood pressure was measured 24 hours ...
-
16 HOW SUPPLIED/STORAGE AND HANDLINGLisinopril tablets USP are available as uncoated biconvex tablets in bottles of below mentioned pack ...
-
17 PATIENT COUNSELING INFORMATIONNOTE: This information is intended to aid in the safe and effective use of this medication. It is not a disclosure of all possible adverse or intended effects. Pregnancy - Advise pregnant women ...
-
PRINCIPAL DISPLAY PANEL
-
INGREDIENTS AND APPEARANCEProduct Information